Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 12
2002 23
2003 42
2004 49
2005 40
2006 39
2007 40
2008 58
2009 62
2010 62
2011 54
2012 47
2013 47
2014 42
2015 42
2016 47
2017 41
2018 40
2019 50
2020 47
2021 44
2022 56
2023 52
2024 50
2025 39

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,018 results

Results by year

Filters applied: . Clear all
Page 1
Bimatoprost Implant: First Approval.
Shirley M. Shirley M. Drugs Aging. 2020 Jun;37(6):457-462. doi: 10.1007/s40266-020-00769-8. Drugs Aging. 2020. PMID: 32447639 Free PMC article. Review.
Bimatoprost implant (Durysta), developed by Allergan, is a sustained-release drug delivery system containing bimatoprost, a prostaglandin analogue with ocular hypotensive activity. ...Allergan's clinical development programme for bimatoprost implant is ongoin …
Bimatoprost implant (Durysta), developed by Allergan, is a sustained-release drug delivery system containing bimatoprost, a pr …
Intracameral sustained release bimatoprost implants (Durysta).
Sirinek PE, Lin MM. Sirinek PE, et al. Semin Ophthalmol. 2022 Apr 3;37(3):385-390. doi: 10.1080/08820538.2021.1985145. Epub 2021 Sep 29. Semin Ophthalmol. 2022. PMID: 34586961 Review.
Many approaches are in development, but this review focuses on Durysta (Allergan plc, Dublin, Ireland), the only FDA-approved sustained release intracameral treatment available at this time. KEY FINDINGS: Durysta is a bimatoprost sustained release (BimSR) intracameral impl …
Many approaches are in development, but this review focuses on Durysta (Allergan plc, Dublin, Ireland), the only FDA-approved sustained rele …
Bimatoprost for the treatment of eyelash, eyebrow and scalp alopecia.
Barrón-Hernández YL, Tosti A. Barrón-Hernández YL, et al. Expert Opin Investig Drugs. 2017 Apr;26(4):515-522. doi: 10.1080/13543784.2017.1303480. Epub 2017 Mar 16. Expert Opin Investig Drugs. 2017. PMID: 28264599 Review.
Areas covered: In this review, the authors evaluate the role of bimatoprost in idiopathic hypotrichosis of the eyelashes, in hypotrichosis of the eyelashes associated to chemotherapy, in alopecia areata of the eyelashes and eyebrows and in androgenetic alopecia. In additio …
Areas covered: In this review, the authors evaluate the role of bimatoprost in idiopathic hypotrichosis of the eyelashes, in hypotric …
Bimatoprost Intracameral Implant (Durysta): A New Era in Glaucoma Management Through Sustained-Release Innovation.
Vagiakis I, Papadopoulou EP, Amaxilati E, Tsiropoulos GN, Konstas AG, Panos GD. Vagiakis I, et al. Drug Des Devel Ther. 2025 Jan 31;19:703-714. doi: 10.2147/DDDT.S506520. eCollection 2025. Drug Des Devel Ther. 2025. PMID: 39906697 Free PMC article. Review.
The bimatoprost intracameral implant (Durysta()) offers a sustained-release approach to glaucoma management, providing consistent intraocular pressure (IOP) reduction over several months and reducing the need for daily topical therapies. ...Future research should explore i …
The bimatoprost intracameral implant (Durysta()) offers a sustained-release approach to glaucoma management, providing consistent int …
Bimatoprost: a novel antiglaucoma agent.
Woodward DF, Phelps RL, Krauss AH, Weber A, Short B, Chen J, Liang Y, Wheeler LA. Woodward DF, et al. Cardiovasc Drug Rev. 2004 Summer;22(2):103-20. doi: 10.1111/j.1527-3466.2004.tb00134.x. Cardiovasc Drug Rev. 2004. PMID: 15179448 Review.
Moreover, patients that are refractory to latanoprost therapy may be successfully treated with bimatoprost. Such evidence provides support, at the clinical level, for the contention that bimatoprost is pharmacologically distinct from PG FP receptor agonist prodrugs. …
Moreover, patients that are refractory to latanoprost therapy may be successfully treated with bimatoprost. Such evidence provides su …
Bimatoprost-induced chemical blepharoplasty.
Sarnoff DS, Gotkin RH. Sarnoff DS, et al. J Drugs Dermatol. 2015 May;14(5):472-7. J Drugs Dermatol. 2015. PMID: 25942665
This better describes the beneficial, as well as the possible negative effects of topical bimatoprost. Although there is a risk for periorbital disfigurement, when used bilaterally, in properly selected candidates and titrated appropriately, bimatoprost can be benef …
This better describes the beneficial, as well as the possible negative effects of topical bimatoprost. Although there is a risk for p …
Bimatoprost: mechanism of ocular surface hyperemia associated with topical therapy.
Chen J, Dinh T, Woodward DF, Holland M, Yuan YD, Lin TH, Wheeler LA. Chen J, et al. Cardiovasc Drug Rev. 2005 Fall;23(3):231-46. doi: 10.1111/j.1527-3466.2005.tb00168.x. Cardiovasc Drug Rev. 2005. PMID: 16252016 Review.
Conjunctival hyperemia is a common side effect of bimatoprost, but the hyperemia is typically mild and transient. No association has been found between signs of inflammation and the presence of hyperemia in bimatoprost-treated patients. ...Results of these studies s …
Conjunctival hyperemia is a common side effect of bimatoprost, but the hyperemia is typically mild and transient. No association has …
Bimatoprost: a pharmacoeconomic review of its use in open-angle glaucoma and ocular hypertension.
Plosker GL, Keam SJ. Plosker GL, et al. Pharmacoeconomics. 2006;24(3):297-314. doi: 10.2165/00019053-200624030-00010. Pharmacoeconomics. 2006. PMID: 16519552 Review.
Bimatoprost was also more effective than twice-daily administration of 0.5%/2% timolol/dorzolamide in patients refractory to topical timolol therapy. ...Various other cost-effectiveness analyses of bimatoprost are available, primarily as abstracts and/or posters. In …
Bimatoprost was also more effective than twice-daily administration of 0.5%/2% timolol/dorzolamide in patients refractory to topical …
Bimatoprost/timolol: a review of its use in glaucoma and ocular hypertension.
Curran MP, Orman JS. Curran MP, et al. Drugs Aging. 2009;26(2):169-84. doi: 10.2165/0002512-200926020-00008. Drugs Aging. 2009. PMID: 19220073 Review.
Topically administered bimatoprost 0.03%/timolol 0.5% ophthalmic solution (bimatoprost/timolol: Ganfort) comprises the synthetic prostamide bimatoprost (structurally related to prostaglandin F2 alpha) and the beta-adrenergic receptor antagonist timolol. Bi …
Topically administered bimatoprost 0.03%/timolol 0.5% ophthalmic solution (bimatoprost/timolol: Ganfort) comprises the synthet …
1,018 results